Skip to main content
menu sluit menu
Home Home
Login
Main navigation
  • Library
  • Calendar
  • e-Learning
  • News
    • Veterinary News In this section you find veterinary news
    • Recent Additions All content that was recently added to the IVIS library
  • Get involved
    • Donate Support IVIS, make a donation today
    • Media kit Promote your e-learning & events on IVIS
    • Add your e-learning & events to the IVIS calendar
    • Publish on IVIS Publish your work with us
  • About
    • Mission Our Mission Statement
    • What we do More info about IVIS and what we do
    • Who we are More info about the IVIS team
    • Authors See list of all IVIS authors and editors
  • Contact
User tools menu
User tools menu
Main navigation
  • Library
  • Calendar
  • e-Learning
  • News
    • Veterinary News In this section you find veterinary news
    • Recent Additions All content that was recently added to the IVIS library
  • Get involved
    • Donate Support IVIS, make a donation today
    • Media kit Promote your e-learning & events on IVIS
    • Add your e-learning & events to the IVIS calendar
    • Publish on IVIS Publish your work with us
  • About
    • Mission Our Mission Statement
    • What we do More info about IVIS and what we do
    • Who we are More info about the IVIS team
    • Authors See list of all IVIS authors and editors
  • Contact
Follow IVIS
  • Twitter
  • Facebook
Support IVIS

Breadcrumb

  1. Home
  2. Library
  3. Concise Review of Veterinary Virology
  4. Prevention of Viral Diseases, Vaccines and Antiviral Drugs
Concise Review of Veterinary Virology - Carter G.R.
Back to Table of Contents
Add to My Library
Close
Would you like to add this to your library?

Get access to all handy features included in the IVIS website

  • Get unlimited access to books, proceedings and journals.
  • Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
  • Bookmark your favorite articles in My Library for future reading.
  • Save future meetings and courses in My Calendar and My e-Learning.
  • Ask authors questions and read what others have to say.
Sign in Register
Comments
Print this article
Share:
  • Facebook
  • LinkedIn
  • Mail
  • Twitter

Prevention of Viral Diseases, Vaccines and Antiviral Drugs

Author(s):
Wise D.J. and
Carter G.R.
In: Concise Review of Veterinary Virology by Carter G.R. et al.
Updated:
MAR 01, 2006
Languages:
  • EN
  • ES
  • PT
Back to Table of Contents
Add to My Library
Close
Would you like to add this to your library?

Get access to all handy features included in the IVIS website

  • Get unlimited access to books, proceedings and journals.
  • Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
  • Bookmark your favorite articles in My Library for future reading.
  • Save future meetings and courses in My Calendar and My e-Learning.
  • Ask authors questions and read what others have to say.
Sign in Register
Print this article
SHARE:
  • Facebook
  • LinkedIn
  • Mail
  • Twitter
    Read

    Table of Contents

    • General
    • Vaccines
    • Passive Immunization
    • Herd Immunity
    • Antiviral Drugs
    • Glossary

    General

    Preventing Infection

    The only certain way to prevent viral infection is to prevent exposure. This is accomplished in practice by only allowing those animals without evidence of previous exposure to commingle. This restricted contact is often referred to as "closed herds". To effectively maintain this closed status, all replacement animals and show animals must be isolated from the remaining animals for at least 2 - 3 weeks.

    During this time, they are monitored for clinical signs and tested serologically (or virologically) for evidence of exposure. Preventing exposure through restricted contact is quite effective in areas where particular viruses are relatively uncommon, but is impractical in areas where these viruses are endemic. In such instances, efforts are redirected from preventing "infection" to preventing disease.

    Controlling Infection and Disease

    Fundamental to controlling viral infections and disease are good management practices. Stress factors play important roles in predisposing animals to infection and in the spread of disease. Particularly important are the stresses associated with poor nutrition, overcrowding, and housing with improper ventilation.

    Management practices should include preventative measures to protect the fetus and the newborn. Some viruses that cause mild or unapparent infections in adult animals may cause abortions or serious disease in neonates (e.g. parvovirus in swine). Thus, efforts should be made to restrict the contact of pregnant animals and newborns from other animals. It is also important to insure that the newborn receives colostrum, which contains antibodies that would confer protection during the first weeks of life.

    Another aspect of good management is the need to minimize contact between different species of animals, as some viruses cause unapparent infections in one species but severe disease in others. An example is the pseudorabies virus, which causes subclinical infections in older pigs but is frequently fatal in piglets, sheep, dogs and cats.

    Thorough cleaning and disinfection, the use of clean coveralls and footbaths, are essential to prevent the spread of viruses by fomites (see Table 6.1). These aspects of management should be practiced at all times, but especially during disease outbreaks. When a disease outbreak occurs, all animals should be quarantined (isolated and observed) and, if indicated, treated symptomatically. For instance:

    • Receive the necessary supportive therapy, as fluid replacement in severe cases of diarrhea.
    • Aqueous sodium chlorite solution is effective for disinfection. See Table 6.1 for other disinfectant choices.
    • Treatment with antibiotics may be advisable to prevent secondary bacterial infection.

    Table 6.1. Some Common Commercially Available Antiviral Disinfectants*

    Disinfectant

    Examples

    Uses

    Comments

    Alcohol

    Ethyl, isopropyl

    Hands, thermometers

    Moderately virucidal at 70 - 80 %; ethanol is preferable

    Chlorhexidine

    Hibitane, Nolvasan

    Many uses including examination tables, cages, other surfaces

    Tolerant to the presence of organic compounds, body fluids, etc.; expensive

    Detergent iodophores

    Betadine, Wescadine, Redene

    Drinking water, food and utensils, dairies, spot disinfection

    Action based release of iodine & detergent action; less affected by high protein; expensive

    Ethylene dioxide

     

    For heat sensitive materials

    Available as a compressed gas at 10% with 90% CO2, otherwise toxic and explosive

    Formaldehyde

    Formalin

    Laundry & bedding surfaces; as a vapor for other surfaces

    Low power of penetration; irritating hypersensitivity occurs

    Glutaraldehyde

    Cidex

    Cold sterilization of instruments with lenses

    2% solution buffered with sodium bicarbonate; virucidal (10 min., pH 7.5 - 8.5); expensive

    Phenol derivatives

    Lysol, Dettol, Staphene, Sudol

    Hands, examination tables, cages, other surfaces

    2.5% aqueous solution; efficacy dependent on concentration and temperature; high protein decreases effectiveness

    Quaternary ammonium compounds

    Zephiran, Roccal, Savlon

    Zephiran (benzalkonium chloride) used for cleaning wounds

    Not effective against many viruses; high protein decreases effectiveness

    Sodium hypochlorite

    Chlorox, Chlorize

    Same as detergent iodophores

    Highly effective, rapid action; high protein decreases effectiveness; irritating; inexpensive

    *This information applies to most viruses; there are some exceptions.

    Vaccines

    In some instances, disease prevention can be accomplished through vaccination. While vaccination doesn't necessarily prevent infection, the previous "priming" of the host's immune system allows for a quick response and clearance of the virus before disease occurs or mild disease of shorter duration. Indeed, vaccination is the most effective and cost-benefit among all preventive measures in animal health.

    There are two principal types of vaccines that are widely used in veterinary practice, those made with killed virus (inactivated) and those prepared with modified-live (attenuated) virus.

    Killed virus vaccines consist of viruses, generally cultivated in tissue culture or embryonated eggs that have been chemically inactivated, often with formalin or beta-propiolactone. These vaccines frequently contain adjuvants to make them more immunogenic. Killed virus vaccines generally require more than one dose to induce immunity and periodic booster doses to maintain adequate immunity. Inactivated vaccines often induce an immunity that is less protective and of shorter duration than that induced by modified live vaccines. Advantages of killed vaccines: they do not revert to virulence and they are safe for use in pregnant and immunocompromised animals.

    Modified-live virus vaccines consist of viruses that have been made less virulent by some means. This is usually accomplished by the serial cultivation of the virus in cell cultures, embryonated eggs, or laboratory animals. Viruses can also be attenuated by deleting specific genes responsible for virulence. This genetic manipulation was used to make a commercially available pseudorabies vaccine. Attenuated vaccines generally confer lifelong immunity, since the vaccine virus replication mimics the natural infection. A sufficiently attenuated live vaccine should not cause disease in healthy vaccinated animals; however, it may cause disease in immunocompromised individuals and fetuses. Some modified-live virus vaccines can be administered by the oral, nasal, or genital (preputial, vaginal) routes where they elicit a local secretory antibody response (IgA).

    The main disadvantage to modified-live vaccines is that some may cause mild disease, lethal infections of the fetus, and the possibility that the attenuated virus may regain its virulence. Live vaccine virus may be transmitted to contact animals.

    Several new approaches are being explored in an effort to make vaccines safer and more effective. Some of these approaches are briefly as follows:

    A subunit vaccine is a type of inactivated vaccine that contains the portions (proteins, fragments) of the virus necessary to induce immunity.

    Synthetic peptides are produced by chemical synthesis of smaller portions (peptides) of viral proteins and employed as more refined subunit vaccines.

    Recombinant vaccines are of three kinds as follows:

    Recombinant proteins:
    The gene for the target viral antigen is cloned and the cDNA introduced to a bacterium or yeast via a plasmid either of which produces large amounts of antigen. This antigen is then used as a vaccine.

    Viral vectors:
    The gene (or genes) from a large virus (usually poxvirus, herpesvirus or adenovirus) is deleted and replaced with a gene (or genes) that encodes the desired antigen (or antigens); the latter are introduced to the animal and expressed in infected cells. The virus that carries the genes of the desired antigen is called a vector.

    Gene-deleted vaccines:
    The virulent virus is made less virulent by gene deletion or by replacing key regions of genes with other genetic material.

    Several recombinant vaccines are being used, including the human hepatitis B virus protein expressed in yeast; rabies virus protein expressed in vaccinia virus; F and HA proteins of canine distemper virus inserted into the genome of canarypox virus.

    Anti-idiotype vaccines: Anti-idiotypic antibodies are made in a two-step process. First an antigen is introduced, to which an organism has an immune response. These antibodies are then used to immunize a second individual, to which an immune response is made. Some of these antibodies have the antigenic characteristics of the original antigen. These are called anti-idiotype antibodies. Thus far anti-idiotype vaccines have only been used experimentally.

    DNA vaccines: In this approach, the viral gene(s) of the protein antigen is introduced to the subject via a plasmid, stimulating the production of a specific, protective viral antibody. Thus far this type of vaccine primarily has been used experimentally. In an effort to find an effective vaccine to prevent a potential influenza pandemic the DNA vaccine approach is being investigated. Their efficacy in humans to generate an appropriate immune response has yet to be established. However, a DNA vaccine has been licensed in the USA for the prevention of West Nile virus infection of horses.

    Marker vaccines: These unique vaccines either lack a characteristic peptide or possess a novel peptide that is not present in the wild type strains of the virus. Thus the missing peptide or novel peptide can serve as a marker for the vaccine strain of a particular virus. They enable diagnostic tests to differentiate between vaccinated and carrier or infected animals. The diagnostic serological test detects antibody to the wild type virus but not to the vaccine altered virus. The methods used to create marker vaccines are gene-deletion (lack of a peptide) or creation of a subunit vaccine (novel peptide). Marker vaccines are commercially available and include pseudorabies (deletion vaccine) and bovine herpes virus -1 (deletion vaccine), vaccines and others are currently being developed for other diseases.

    In Ovo Vaccination

    This form of vaccination is practiced for the prevention of Marek’s disease.

    Embryonated eggs are inoculated with an automatic device at 18 days of incubation. The procedure, which is safe and effective, is also used to vaccinate against infectious bronchitis and infectious bursal disease.

    In general, effective vaccines are available for those viruses that have one or a few stable antigenic types and that can be obtained in sufficient quantity for vaccine preparation. Interestingly, it is because of antigenic instability that the composition of the human influenza vaccine has to be regularly (annually) changed, in accordance with the current strains circulating among the population.

    Passive Immunization

    Passive immunization refers to the transfer of immunoglobulins to non-immune individuals. The immunoglobulins present in immune sera contain neutralizing antibodies that prevent the attachment of the specific virus to susceptible cells. Natural passive immunity includes the receipt of maternal antibodies via placenta (IgG), colostrum (IgG) or the amniote egg yolk (IgY). Receipt of inadequate levels of maternal antibody can result in high morbidity and mortality rates for many viral diseases of young animals.

    In clinical practice, immunoglobulins are generally given before exposure or during the incubation period to modify the infection. Antiserum (produced in donor animals) protects for a short period of time and has very limited use in the prevention of viral diseases. Antisera have been used to prevent canine distemper, feline panleukopenia and West Nile virus infection in horses. In some horse and cattle herds, storage of colostrum with subsequent administration to neonates is used to increase their immunity.

    Herd Immunity

    This phenomenon occurs when a sufficiently large proportion of a population ("herd") has been immunized and thus is immune to a particular virus. An individual that may eventually lack immunity to the same virus is then protected, as the remainder of the herd is incapable of transmitting the virus. In order to be effective, the vaccine in question must prevent the disease caused by the virus and its transmission. A similar effect can be seen with natural disease, if the majority of a population had recovered from a disease and possesses long-term immunity, then a few non-infected individuals could be protected by herd immunity as long as there were no reservoir animals in the herd.

    Antiviral Drugs

    Antiviral drugs have had very limited veterinary use. It seems likely that some of these drugs will be effective against animal viruses that are closely related to the human viruses against which they have shown efficacy.

    These drugs can be separated into two large categories based upon mode of action. These are the nucleoside analogs and non-nucleoside analogs discussed below.

    In 2006, the CDC reported that a human type A flu strain had developed resistance to two commonly used antiviral drugs, rimantadine and amantadine. The flu strain H3N2, predominant in the flu season, once routinely treated with these antiviral drugs has developed resistance. This information supports the need for the development of additional antiviral drugs and potentially the use of antiviral drug cocktails for treatment of influenza.

    Nucleoside Inhibitors

    Many of the commercially available antiviral drugs are nucleoside analogs, which affect viral nucleic acid polymerases. The more common of these are: acycloguanosine (acyclovir), dihydroxypropoxy-methylquanine (ganciclovir), adenine~arabinoside (vidarabine), and azidothymidine (zidovudine). See Table 6.2 for a list of some of the nucleoside inhibitors and typical viruses they are used to treat.

    Antiviral drugs are not widely used, in veterinary medicine. Acyclovir is effective against herpesviruses and has been used to treat ocular herpesvirus infection of cats. This drug has also been used to prophylactically treat expensive psittacine birds that have been exposed to psittacine herpesvirus.

    Table 6.2. Properties of Various Nucleoside Inhibitors

    Nucleoside Inhibitor

    Type of Analog

    Viruses Targeted

    Acyclovir

    Guanosine analog

    Herpes simplex virus

    Varicella-zoster virus

    Ganciclovir

    Guanosine analog

    Cytomegalovirus

    Cidofovir

    Cytosine analog

    Cytomegalovirus

    Human papillomavirus

    Vidarabine

    Adenine with arabinose sugar

    Herpes viruses

    Iododeoxyuridine

    Thymine analog; iodine in place of methyl group

    Herpes simplex virus

    Trifluorothymidine

    Thymine analog; 3 fluorine atoms in place of 3 hydrogen atoms

    Herpes simplex virus

    Azidothymidine

    Thymine analog; azide group in place of hydroxyl group of ribose

    Human Immunodeficiency virus

    Dideoxyinosine

    Inosine lacking the 3'-OH group

    Human Immunodeficiency virus

    Dideoxycytidine

    Cytosine lacking the 3'-OH group

    Human Immunodeficiency virus

    Stavudine

    Thymine analog

    Human Immunodeficiency virus

    Lamivudine

    Cytosine analog

    Human Immunodeficiency virus

    Hepatitis B virus

    Abacavir

    Guanosine analog

    Human Immunodeficiency virus

    Tenofovir

    Adenosine monophosphate analog

    Human Immunodeficiency virus

    Ribavirin

    Guanine precursor analog

    Respiratory syncytial virus

    Influenza B virus

    Non-Nucleoside Inhibitors

    Interferons and antiviral drugs are used for the specific treatment of viral diseases. Interferons were previously discussed in detail in chapter 5. They are of importance in antiviral therapy as interferons appear early in infection and play a major role in recovery. The mode of action is the inhibition of viral protein synthesis.

    The treatment of animals with exogenous interferon is not practiced widely because of the general unavailability of host-species interferons. While interferons are not necessarily host-species specific, their action is dependent upon their ability to bind to specific cell surface receptors. Human α-interferon, which is commercially available as a DNA recombinant, has some cross-species activity and has been used to orally treat cats infected with feline leukemia virus.

    • In addition to interferons, other drugs that inhibit viral mRNA translation are fomiversin and methisazone. Fomiversin (Vitravene) is an antisense DNA that blocks replication of cytomegalovirus. Methisazone (N-methylisatin-β-thiosemicarbazone) is specific for poxvirus mRNA.
    • Amantadine (Symmetrel) and rimantadine (Flumadine) interfere with the penetration and/or uncoating of many enveloped viruses, but is effective only against influenza A infections in humans. These antivirals are not commonly used in the U.S.
    • Saquinavir (Invirase), indinavir (Crixivan), ritonavir (Norvir), and nelfinavir (Viracept) are inhibitors of viral proteases. They act by binding the active site of the protease, inhibiting the enzyme from cleaving other proteins. These drugs are often used in drug cocktails for the treatment of HIV infection in humans.
    • Zanamivir (Relenza) and oseltamivir (Tamiflu) inhibit the release of virus from the host cell. They are specific for the neuraminidase of influenza virus, prevent release, and thereby limit spread of the virus.

    Glossary

    Adjuvants:

    Substances or chemical formulations used to enhance the immune response to inactivated vaccines. They act by retaining the immunogen at the injection site, as by a depot effect, and thus delaying its release; the antigenic stimulation is prolonged and consequently increased. Some adjuvants may also stimulate macrophages, lymphocytes and other cells involved in the immune response. Salts of metals, such as those of aluminum, oil emulsions (Freund's adjuvants), and synthetic lipid vesicles (liposomes) are some of the adjuvants used.

    Neuraminidase:
    A glycoprotein which is present as a spike on the outside of the influenza virus envelope. It breaks down an inhibitor of the influenza virus hemagglutinin protein.

    Back to Table of Contents
    Add to My Library
    Close
    Would you like to add this to your library?

    Get access to all handy features included in the IVIS website

    • Get unlimited access to books, proceedings and journals.
    • Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
    • Bookmark your favorite articles in My Library for future reading.
    • Save future meetings and courses in My Calendar and My e-Learning.
    • Ask authors questions and read what others have to say.
    Sign in Register
    Print this article
    Comments (0)

    Ask the author

    0 comments
    Submit
    Close
    Would to like to further discuss this item?

    Get access to all handy features included in the IVIS website

    • Get unlimited access to books, proceedings and journals.
    • Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
    • Bookmark your favorite articles in My Library for future reading.
    • Save future meetings and courses in My Calendar and My e-Learning.
    • Ask authors questions and read what others have to say.
    Sign in Register
    About

    How to reference this publication (Harvard system)?

    Wise, D. J. and Carter, G. R. (2005) “Prevention of Viral Diseases, Vaccines and Antiviral Drugs”, Concise Review of Veterinary Virology. Available at: https://www.ivis.org/library/concise-review-of-veterinary-virology/prevention-of-viral-diseases-vaccines-and-antiviral (Accessed: 20 March 2023).

    Affiliation of the authors at the time of publication

    1Department of Biology, Concord University, Athens, West Virginia, USA.2Virginia-Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, Virginia, USA.

    Author(s)

    • Darla Wise

      Wise D.J.

      Associate Professor
      MS PhD
      Department of Biology, Concord University
      Read more about this author
    • Carter G.R.

      Professor Emeritus
      DVM MS DVSc
      Department of Biomedical Sciences and Pathobiology, Virginia-Maryland Regional College of Vet Medicine, Virginia Polytechnic Institute & State University
      Read more about this author

    Copyright Statement

    © All text and images in this publication are copyright protected and cannot be reproduced or copied in any way.
    Related Content

    Readers also viewed these publications

    • Journal Issue

      Veterinary Evidence - Vol 7 N°3, Jul-Sep 2022

      In: Veterinary Evidence
      OCT 04, 2022
    • Journal Issue

      Veterinary Practice Management Articles - Veterinary Focus

      In: Veterinary Focus
      AUG 05, 2022
    • Journal Issue

      Canine and Feline Nutrition - Veterinary Focus - Vol. 24(3) - Nov. 2014

      In: Veterinary Focus
      MAR 04, 2021
    • Journal Issue

      Canine Health and Welfare - Veterinary Focus - Vol. 30(3), December 2020

      In: Veterinary Focus
      JAN 15, 2021
    • Journal Issue

      COVID-19, Special Practice Management - Veterinary Focus - May 2020

      In: Veterinary Focus
      MAY 28, 2020
    • Journal Issue

      The C-Factor: Vet Skills in Communication - Veterinary Focus - Mar. 2020

      In: Veterinary Focus
      MAY 01, 2020
    • Proceeding

      AAVPT - Biennial Symposium - Overland Park, 2019

      By: American Academy of Veterinary Pharmacology & Therapeutics
      AUG 23, 2019
    • Journal Issue

      Kittens and Young Cats - Veterinary Focus - Vol. 29(1), Mar. 2019

      In: Veterinary Focus
      MAR 01, 2019
    • Journal Issue

      Enfermedades emergentes en porcino - Albéitar - N°222, Ene-Feb. 2019

      In: Albéitar
      FEB 01, 2019
    • Journal Issue

      Improving the pet owner experience in your practice - Veterinary Focus - Special Issue

      In: Veterinary Focus
      APR 01, 2018
    • Chapter

      Flaviviridae

      In: Concise Review of Veterinary Virology
      DEC 19, 2008
    • Chapter

      Understanding Cryogenic Liquid Nitrogen Tanks

      In: Reviews in Veterinary Medicine
      MAY 14, 2007
    • Chapter

      Arteriviridae

      In: Concise Review of Veterinary Virology
      SEP 08, 2006
    • Chapter

      Circoviridae

      In: Concise Review of Veterinary Virology
      SEP 05, 2006
    • Chapter

      Occupational Health in Animal Care, Use and Research

      In: Laboratory Animal Medicine and Management
      JUL 26, 2006
    • Chapter

      Orthomyxoviridae

      In: Concise Review of Veterinary Virology
      MAY 09, 2006
    • Chapter

      Herpesviridae

      In: Concise Review of Veterinary Virology
      MAY 09, 2006
    • Chapter

      Prions and Transmissible Spongiform Encephalopathies

      In: Concise Review of Veterinary Virology
      DEC 14, 2005
    • Chapter

      Cumulative Glossary

      In: Concise Review of Veterinary Virology
      DEC 14, 2005
    • Chapter

      Coronaviridae

      In: Concise Review of Veterinary Virology
      DEC 14, 2005
    • Chapter

      Index of Diseases

      In: Concise Review of Veterinary Virology
      DEC 14, 2005
    • Chapter

      Togaviridae

      In: Concise Review of Veterinary Virology
      DEC 14, 2005
    • Chapter

      Families with Viruses of Minor Veterinary Significance

      In: Concise Review of Veterinary Virology
      DEC 14, 2005
    • Chapter

      Picornaviridae

      In: Concise Review of Veterinary Virology
      NOV 21, 2005
    • Chapter

      Caliciviridae

      In: Concise Review of Veterinary Virology
      NOV 21, 2005
    • Load more
    Back To Top
    Become a member of IVIS and get access to all our resources
    Create an account
    Sign in
    Leading the way in providing veterinary information
    About IVIS
    • Mission
    • What we do
    • Who we are
    Need help?
    • Contact
    Follow IVIS
    • Twitter
    • Facebook
    International Veterinary Information Service (IVIS) is a not-for-profit organization established to provide information to veterinarians, veterinary students, technicians and animal health professionals worldwide using Internet technology.
    Support IVIS
    © 2023 International Veterinary Information Service
    • Disclaimer
    • Privacy Policy